View:

Download DOC

Download PDF

Download XLS

144: Filer Information

Filer CIK	0001340881
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jounce Therapeutics, Inc.
SEC File Number	001-37998
Address of Issuer	780 MEMORIAL DRIVE CAMBRIDGE MASSACHUSETTS 02139
Phone	857-259-3840
Name of Person for Whose Account the Securities are To Be Sold	Drapkin Kimberlee C
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Common Stock
Name and Address of the Broker	ETrade Financial Corporation 3 Edison Drive Alpharetta GA 30005
Number of Shares or Other Units To Be Sold	15000
Aggregate Market Value	17100.00
Number of Shares or Other Units Outstanding	51694237
Approximate Date of Sale	01/09/2023
Name the Securities Exchange	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Common Stock
Date you Acquired	01/06/2023
Nature of Acquisition Transaction	Vesting of restricted stock units
Name of Person from Whom Acquired	Issuer
Is this a Gift? Date Donor Acquired
Amount of Securities Acquired	25483
Date of Payment	01/06/2023
Nature of Payment	(1)

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	(1) The securities to be sold were received upon the settlement of vested restricted stock units. Under the applicable plan and award agreement, upon vesting, restricted stock units are settled in shares of Common Stock on a 1-for-1 basis without any payment.
Date of Notice	01/06/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/16/2018
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Caroline Gammill, attorney-in-fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS
Know all by these present, that the undersigned hereby makes,
constitutes and appoints each of Jacquelyn Fahey
Sandell, Elizabeth Shortsleeve and Caroline Gammill, signing singly
and each acting individually, as the undersigned s true and lawful
attorney in fact with full power and authority as hereinafter described
to:
(i) execute for and on behalf of the undersigned, in the undersigned's
 capacity as a director, officer and or stockholder  of
Jounce Therapeutics, Inc. (the Company), Forms 3, 4, and 5
(including any amendments thereto) in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder
 (the Exchange Act) and/or Forms 144 (including any amendments thereto)
 in accordance with Rule 144 (Rule 144)
 under the Securities Act of 1933, as amended (the Securities Act);
(ii) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to prepare, complete
and execute any such Form 3, 4, or 5 or Form 144, prepare, complete and execute
 any amendment or amendments thereto, and timely deliver and file such form
with the United States Securities and Exchange Commission (the SEC) and
any stock exchange or similar  authority, including without limitation the
execution and filing of a Form ID or any other application materials
to enable the undersigned to gain or maintain access to
the Electronic Data Gathering, Analysis and Retrieval system
 of the SEC;
(iii) seek or obtain, as the undersigned's representative and on
the undersigned's behalf, information regarding transactions in
the Company's securities from any third party, including
brokers, employee benefit plan administrators and trustees, and the
undersigned hereby authorizes any such third party to release
any such information to the herein appointed attorney in fact and
approves and ratifies any such release of information; and
(iv) take any other action of any type whatsoever in connection
with the foregoing  which, in the opinion of such
attorney in fact, may be of benefit to, in the best interest
of, or legally required by, the undersigned,  it being understood
that the documents executed by such attorney in fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as
such attorney in fact may approve in such attorney in fact's discretion.

The undersigned hereby grants to each such attorney in fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of
the rights and powers herein granted,
as fully to all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the rights and
powers herein granted.
The undersigned acknowledges that the foregoing attorneys in fact,
in serving in such capacity at the request of the undersigned, are not assuming
nor relieving, nor is the Company assuming nor relieving, any of the
undersigned s responsibilities to comply with Section 16 of the
Exchange Act or Rule 144 of the Securities Act.
The undersigned acknowledges that neither the Company
nor the foregoing attorneys in fact assume (i) any liability for
the undersigned s responsibility to comply with the requirement
of the Exchange Act,
(ii) any liability of the undersigned for any failure to comply with such
requirements, or (iii) any obligation or liability of the undersigned
for profit disgorgement under Section 16(b) of the Exchange Act.
This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, and or Forms 144
with the SEC with respect to the undersigned's holdings of and transactions
 in securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to the foregoing attonreys in fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 4th day of January, 2023.
/s/ Kim C. Drapkin
Name: Kim C. Drapkin